Yorvipath was granted marketing authorization by the european commission (ec) in november 2023 as a pth replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. The fda has approved yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism Is yorvipath right for me Your health care provider may consider treatment with yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin d treatment. What does research show about yorvipath for hypoparathyroidism The fda approved yorvipath based on evidence from a clinical trial involving 82 adults with chronic hypoparathyroidism.
The food and drug administration (fda) has approved yorvipath (palopegteriparatide Developed as transcon pth) for the treatment of hypoparathyroidism in adults The table below summarizes the three key therapies—natpara, forteo, and yorvipath—with attention to their origin, approval status, and role in clinical practice Comparison of pth replacement therapies for hypoparathyroidism Yorvipath on august 12th 2024, ascendis pharma announced that the fda had approved yorvipath (palopegteriparatide), their new parathyroid hormone, as a treatment for chronic hypoparathyroidism in adults in the united states You can read their press release official press release what is yorvipath?
WATCH
